:
Chemoresistance is one of the biggest hurdles while treating cancer clinically. Due to its heterogeneous nature, complications of the chemoresistance mechanisms of breast cancer are cannot be completely elucidated. Existing mechanisms of main-line drug treatment can slow down the process of malignancy with part and parcel called drug resistance. The combinatorial effect of several chemotherapeutic drugs, targeting different pathways at the same time can work efficiently, yet the toxicity and drug-drug interaction remain intact.
To overcome this hurdle, a number of strategies are getting invented, such as novel agents, drug carriers and combination treatment, etc. target mediated drug delivery system; nano-medicine and the use of phytocompounds can transfer the drug particularly to the cancerous cells with minimal side effects to the neighboring healthy cells. The cell cycle checkpoint proteins and genes are induced to the deranged cells can inhibit the resistance mechanism towards the drug. Modification of cell signaling pathways can also help to treat breast cancer chemoresistance mechanism in the long run. This article reviews the execution and onset of chemoresistance in various cancers and would further discuss potential therapeutic approaches to deal with the resistance mechanism.
In this review, we’ll try to summarize the possible mechanisms and signaling pathways causing chemoresistance in breast cancer cell lines and discuss the alternative therapy to overcome under pre-clinical and clinical infrastructure.
Integrated analysis of breast cancer cell lines reveals unique signaling pathways
